AlphAIAlphAI — Financial news for AI agents
fool.com$IRIX

IRIDEX (IRIX) Q2 2026 Earnings Call Transcript

IRIDEX (IRIX) reported Q2 2026 revenue of $12.6M, down 7% YoY, with Cyclo G6 product revenue up 19% but retina revenue down. Net loss was $1.3M. Management maintained full-year revenue guidance of $51M-$53M, excluding Middle East revenue, and expects low-double-digit glaucoma growth and low-single-digit retina growth in H2 2026.

Original reporting
fool.com
Published Aug 26, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 12:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IRIDEX (IRIX) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$IRIXNeutralMed
01

Why it matters

The earnings release provides fresh guidance and cash flow data, informing short‑term trading decisions.

02

Market read

First‑hand earnings data for a micro‑cap ophthalmic device company; relevant for sector‑specific traders.

03

What to watch

Potential upcoming MDR approval for PASCAL platform in 2027 may unlock future upside.

Relevance 6/10Novelty 7/10Timing: after‑hours release

Background

IRIDEX reported Q2 2026 results, highlighting mixed performance across product lines and ongoing operational transitions.

Company-level read

Ticker impact

$IRIXNeutralMedium confidence
Context

Q2 2026 earnings released with revenue down 7% YoY, net loss of $1.3M and full-year guidance unchanged.

Expected impact

Potential modest dip on earnings miss, but support near current levels due to cash flow positivity.

Evidence & confidence

Revenue decline and loss signal weakness, yet cash generation and unchanged guidance reduce risk of a sharp sell‑off.

Market effects

Sector

Glaucoma and retina device makers may see similar pressure from international regulatory transitions.

Regional

Middle East disruptions could affect other med‑tech firms with exposure in that region.

Global

Limited to ophthalmic device niche; broader market impact minimal.

Counterpoint

What could challenge this read

Despite revenue decline, the cash flow turn‑around and inventory build‑up could support a rebound.

Key entities

  • Executive
    Patrick Mercer

    CEO of IRIDEX, provided forward‑looking statements.

  • Executive
    Romeo R. Dizon

    CFO of IRIDEX, presented financial details.

Read at source← All news

Related articles

$IRIXMedAI 8/10

Iridex Reports Sustained Glaucoma Benefits With MicroPulse Laser Therapy At Two Years

Iridex (IRIX) reported a two-year study showing sustained IOP reductions and lower medication use in glaucoma patients treated with its MicroPulse laser therapy. The study, published in the International Journal of Ophthalmology, involved 84 eyes from 53 patients. Mean IOP decreased from 22.32 mmHg to 14.05 mmHg, and medication use fell from 2.96 to 2.38. IRIX shares traded between $0.61 and $1.65 over the past year, closing at $0.89 on Friday.

rttnews.com
$IRIXLowAI 8/10

Iridex reports 2-year glaucoma study shows sustained IOP reduction

Iridex (IRIX) reported a 2-year study showing sustained intraocular pressure reduction in glaucoma patients using its MicroPulse Technology. The study, published in the International Journal of Ophthalmology, involved 84 eyes of 53 patients. Mean intraocular pressure decreased from 22.32 mmHg to 14.05 mmHg over 24 months. The company manufactures laser-based medical systems for ophthalmology.

investing.com
$IRIXMedAI 8/10

Iridex study shows two-year glaucoma treatment outcomes

Iridex Corporation (IRIX) published a two-year study on glaucoma treatment using its MicroPulse Technology, showing significant intraocular pressure reduction and medication decrease. The study, led by Dr. Michele Lanza, was published in the International Journal of Ophthalmology and reported no complications. Iridex manufactures laser-based medical systems for glaucoma and retinal diseases.

investing.com
$IRIXMedAI 8/10

A glaucoma laser treatment lowered eye pressure and medicine use over two years.

Iridex Corporation announced a two-year study showing its MicroPulse TLT laser treatment reduced intraocular pressure and medication use in glaucoma patients. The study, published in the International Journal of Ophthalmology, involved 84 eyes of 53 patients. Mean IOP decreased from 22.32 mmHg to 14.05 mmHg, and medication use dropped from 2.96 to 2.38. The company's CEO highlighted the positive outcomes and commitment to advancing glaucoma treatments.

stocktitan.net
$IRIXMed

IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 Surges 35% as Company

IRIDEX Corp (IRIX) reported Q2 2026 earnings, highlighting a 35% surge in Cyclo-G6 probe sales. CEO Patrick Mercer expects low single-digit retina growth for the year, driven by regulatory approvals and promotions, despite headwinds in the Middle East and China. The company placed fewer Cyclo-G6 systems due to regulatory delays but anticipates higher numbers in Q4. Glaucoma growth was broad-based, with strong US and international performance. Revenue decline was attributed to retina business and

yahoo.com
$IRIXMed

Iridex Reports Second Quarter 2026 Financial Results

IRIDEX CORP (IRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Iridex Reports Second Quarter 2026 Financial Results MOUNTAIN VIEW, Calif., August 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for

SEC EDGAR 8-K